Prognostic factors and survival analysis in a sample of oral squamous cell carcinoma patients

Survival Following Non Surgical Treatments for Oral Cancer: a Single Institutional Result

“…Also, the association between sex and survival is controversial. In some reports there is no difference between male and female patients (Chandu et al, 2005;Montoro et al, 2008) whereas in some others male patients have lower survival (Yeole et al, 2003;Oliveira et al, 2008). In the present study survival between male and female gender was not significant (p=0.74).…”

“…Asian Pacific Journal of Cancer Prevention, Vol 13, 2012 4135 DOI:http://dx.doi.org/10.7314/APJCP.2012.13.8.4133 Survival Following Non Surgical was 28.6% (Oliveira et al, 2008). In Malay the 5-year survival has been 18% (Razak et al, ????).…”

“…The prognostic importance of age and sex is not clear in literature. In some studies young patients had better outcome (Yeole et al, 2003;Oliveira et al, 2008). In one study radiotherapy outcome was inferior in those patients below the age of 40 years (Murthy et al, ????).…”

Functional Biomarkers of Oral Cancer

“…The tumor suppressor p53 is one of the most studied biomarkers in OSCC, as well as in other malignancies. The high expression of p53 is especially detected at advanced stages of carcinogenesis, and is also associated with a poor prognosis (Oliveira et al, 2007a(Oliveira et al, , 2007b(Oliveira et al, , 2008, while the clinical significance of that of p63, a p53 homologue, remains controversial (Oliveira et al, 2007a(Oliveira et al, , 2007bLo Muzio et al, 2005a, 2007. Mutation of p53 occurs in 50% of OSCC cases (Ogden et al, 1992(Ogden et al, , 1996, which might be pertinent to consequent overexpression of this molecule.…”

Expressão imuno-histoquímica da topoisomerase III? nos carcinomas mamários

“…Na população mundial, a sobrevida média cinco anos após o diagnóstico varia entre 75 a 88%, muito acima da média dos outros tumores, com 61% (COLEMAN et al, 2008;SOERJOMATARAM et al, 2008). Estes números foram possíveis não só pelo rastreamento precoce de tumores, mas também pela pesquisa ativa por biomarcadores de importância prognóstica, que são importantes ferramentas para definir o tratamento e para estimar o curso clínico da doença (SOERJOMATARAM et al, 2008 O p53 tem sido estudado como um fator de prognóstico em diversos tipos de tumores, entre eles os de cólon, de mama e no carcinoma epidermóide oral (OLIVEIRA et al, 2008;KIM et al, 2009;KIM et al, 2010;PANCIONE et al, 2010). O p53 também demonstrou, em alguns trabalhos clássicos, ser um forte preditor de recorrência e sobrevida (THOR et al, 1992;ISOLA et al, 1992).…”